Evaxion Biotech A/S
NASDAQ:EVAX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Evaxion Biotech A/S
NASDAQ:EVAX
|
DK |
|
P
|
Pioneer Cement Ltd
KAR:PIOC
|
PK |
|
Z
|
Zinc Media Group PLC
LSE:ZIN
|
UK |
|
T
|
Telkom Indonesia (Persero) Tbk PT
XBER:TCID
|
ID |
|
77 Bank Ltd
TSE:8341
|
JP |
Evaxion Biotech A/S
Evaxion Biotech A/S is a biotechnology company that uses artificial intelligence to design immune-based medicines. Its main work is to discover and develop vaccine and immunotherapy candidates for cancer and infectious diseases, then move the most promising ones through early-stage testing. The company does not sell a mass-market product; it sells scientific development programs and the rights to those programs. Its customers and partners are usually larger drug companies, research collaborators, and eventually healthcare systems that would buy approved treatments. Evaxion makes money mainly through collaboration payments, research funding, milestone payments tied to development progress, and future royalties or licensing income if a product reaches the market. That means its business depends on turning its science into assets that another company can help develop and commercialize. What makes Evaxion different is its role in the drug discovery chain. Instead of using AI to manage patients or automate labs, it uses AI to choose which disease targets and immune responses are most likely to work. In simple terms, it tries to improve the odds of finding effective vaccines and immunotherapies by making the early research process more focused and data-driven.
Evaxion Biotech A/S is a biotechnology company that uses artificial intelligence to design immune-based medicines. Its main work is to discover and develop vaccine and immunotherapy candidates for cancer and infectious diseases, then move the most promising ones through early-stage testing. The company does not sell a mass-market product; it sells scientific development programs and the rights to those programs.
Its customers and partners are usually larger drug companies, research collaborators, and eventually healthcare systems that would buy approved treatments. Evaxion makes money mainly through collaboration payments, research funding, milestone payments tied to development progress, and future royalties or licensing income if a product reaches the market. That means its business depends on turning its science into assets that another company can help develop and commercialize.
What makes Evaxion different is its role in the drug discovery chain. Instead of using AI to manage patients or automate labs, it uses AI to choose which disease targets and immune responses are most likely to work. In simple terms, it tries to improve the odds of finding effective vaccines and immunotherapies by making the early research process more focused and data-driven.
Milestones: Evaxion said it hit its first 2026 milestone with encouraging EVX-01 translational and immunogenicity data, and it expects more updates later this year at a scientific meeting.
EVX-01: The lead melanoma program showed an 86% immunogenicity conversion rate and an 86% de novo T-cell response rate, adding to prior clinical data that included a 75% overall response rate, 25 complete responders, and 92 sustained responses.
Platform breadth: Management used new data in glioblastoma and polio to argue that its AI-Immunology platform can work across oncology, infectious disease, and potentially autoimmune disease.
Cash: Q1 financials were described as in line with plan, with cash of $18.4 million, a net loss of $3.6 million, and runway into the second half of 2027.
Partnerships: Business development was highlighted as a major priority, with management saying discussions are ongoing across both cancer and infectious disease assets but no specific deal details were shared.
